KIMBERLY DIAZ: Open Payments
NPI 1366623639 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$688 in 42 payments from 13 companies in 2025. Trend: 2023 $722 · 2024 $926 · 2025 $688
Food & beverage: $688
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $164 |
| Novo Nordisk Inc | 10 | $163 |
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
| GlaxoSmithKline, LLC. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $34 |
| Seqirus USA Inc | 2 | $32 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Exact Sciences Corporation | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
Products named: Kerendia, Ozempic, AIRSUPRA, Rybelsus, CAPLYTA, JARDIANCE, Fluad, GEMTESA.
Industry payments across TX — which companies pay providers there.
